| Previous close | 90.11 |
| Open | 90.09 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 89.70 - 91.44 |
| 52-week range | 80.60 - 104.32 |
| Volume | |
| Avg. volume | 1,400,194 |
| Market cap | 112.81B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 25.01 |
| EPS (TTM) | 3.61 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 3.76 (4.17%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | 106.60 |
ZacksDenali's (DNLI) Candidate Selected for FDA's START Pilot Program
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
GlobeNewswirePress Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patientsKey primary endpoint of progressio
BloombergGSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege S
